University of Illinois

Pharmascience Inc.

John M Pezzuto

Tapas K DasGupta

Jerome W Kosmeder, Ii

Darrick S Kim

Richard C Moon

Darrick S H L Kim

Ze-Qi Xu

Nian E Zhou

Alan D Kinghorn

Miriam Elaine Goldsmith

Mei-Shiang Jang

Aomar Ouali

Robert M Moriarty

A Douglas Kinghorn

Baoliang Cui

Karla Slowing Barillas

Gloria L Silva

Lynda Li Song

Min You

Lydia Ling-Indeck

Konrad Marc Kuzmanoff

Krishna P L Bhat

Mary Lou Schmidt

Dongho Lee

Cesar M Compadre

Shengzhao Lin

Compositions and methods are disclosed for treating melanoma wherein a betulinic acid derivative is the active compound in the composition to be administered. The compositions are optionally applied topically is inserted therefor.

Method and composition for selectively inhibiting melanoma

A composition and method of preventing or inhibiting tumor growth and, more particularly, of treating a malignant tumor, using prodrugs of plant-derived compounds and derivatives is disclosed. In the method, a composition containing betulinic acid or a betulinic acid derivative is administered in a prodrug form to release betulinic acid or a betulinic acid derivative in vivo at the tumor site.

Method of preparing and use of prodrugs of betulinic acid derivatives

Compounds and methods of modulating the activity of P-glycoproteins are disclosed. The method utilizes compounds derived fromThe compounds overcome multidrug resistance and can be used therapeutically to enhance performance of therapeutic drugs, like chemotherapeutic drugs and antibiotics.

[object Object]

A composition and method of cancer treatment is disclosed. The composition and method utilized the extract of , or compounds included therein having aromatase inhibition properties, as active cancer chemopreventative and treating agents in mammals, including humans.

Aromatase inhibitors from Broussonetia papyrifera

A composition and method of preventing or inhibiting tumor growth, and of treating malignant melanoma, without toxic side effects are disclosed. Betulinic acid or a betulinic acid derivative is the active compound of the composition, which is topically applied to the situs of tumor.

A method is provided for preventing or treating skin conditions, disorders or diseases, such as may be associated with or caused by inflammation, sun damage or natural aging. The method involves administration, preferably topical administration, of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing. Pharmaceutical formulations for use in conjunction with the aforementioned method are provided as well.

Pharmaceutical formulations of resveratrol and methods of use thereof

A composition and method of cancer chemoprevention is disclosed. The composition and method utilize 4'-bromoflavone as a cancer chemo-preventative agent in mammals, including humans.

Use of 4'-bromoflavone in a cancer chemopreventative composition and

A composition and method of cancer chemoprevention is disclosed. The composition and method utilize resveratrol as a cancer chemopreventative agent in mammals, including humans.

Cancer chemopreventative composition and method

A composition and method of preventing or inhibiting tumor growth, and of treating malignant cancers without toxic side effects are disclosed. Betulinic acid or a betulinic acid derivative is the active compound of the composition.

Method and composition for treating cancers

Improved methods of manufacturing betulinic acid from betulin are disclosed. The methods provide the .beta.-isomer of betulinic acid in high purity and high yield.

Methods of manufacturing betulinic acid

A composition and method of inhibiting tumor growth and treating malignant melanoma without toxic side effects are disclosed. Betulinic acid or a betulinic acid derivative is the active compound of the composition, which is topically applied to the situs of tumor. Betulinic acid is obtained by the steps of preparing an extract from the stem bark of Ziziphus mauritiana to mediate selective cytotoxic profile against human melanoma in the subject panel of human cancer cell lines, conducting a bioassay-directed fractionation based on the profile of biological activity using cultured human melanoma cells as the monitor, and obtaining betulinic acid.

Method and composition for selectively inhibiting melanoma using

Racemic hernandulcin, a sesquiterpene, possesses a sweetness intensity about three orders of magnitude greater than that of sucrose. It is non-mutagenic and non-toxic under conventional assay procedures. In addition to attractive utility in foods, beverages and pharmaceutical compositions, it affords a low-cariogenic, essentially non-nutritive sweetening agent for inclusion in oral hygiene products.

Growing community of inventors

River Forest, IL, United States of America

John M Pezzuto